This webinar was recorded live on January 30, 2024.
It is available on demand through January 31, 2025.
Register above for access.
Description
Technological improvements have led to new and better methods for identifying and diagnosing medical conditions, while streamlining the delivery of patient care and improving outcomes. These advancements have also created challenges for laboratories and payers alike, as labs often need to modify their operations to accommodate the new technologies, while insurers struggle with applying existing coverage and payment policies to the tests.
The second in a series, this webinar will use case studies involving cardiac troponin and pharmacogenetics to examine the clinical and operational aspects of implementing a novel technology, provide tools for measuring whether a new method improves the delivery of patient care, and evaluate the financial challenges of a new test for the laboratory, patient, and insurer.
The speakers will also offer practical strategies for addressing these management and fiscal issues.
Target Audience
This activity is designed for lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, and other laboratory professionals overseeing/conducting within this topic.
Learning Objectives
At the end of this session, participants will be able to:
- Describe the changing role of technology in laboratory medicine.
- Explain how to successfully assess and introduce new technologies.
- Discuss strategies for justifying coverage and payment from insurers.
Faculty
Peter Kavsak, PhD, FCACB, FCCS
Professor, Department of Pathology and Molecular Medicine, McMaster University
Scientist, Hamilton Health Sciences
Clinical Chemist, Hamilton Regional Laboratory Medicine Program
Hamilton, Ontario, Canada
Sara Rogers, PharmD
President, American Society of Pharmacovigilance
Clinical Assistant Professor, Texas A&M University
Residency Program Director, PGY2 Ambulatory Care, Texas A&M Health Family Care Clinic
Houston, Texas USA
Ruben Bonilla Guerrero, MD, DABMG, FACMG, FADLM, MB(ASCP), NY(CQ), CGMBS
CEO and CMO, Genetica Consulting
Laguna Niguel, CA USA
Disclosures and Statement of Independence
The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported financial relationships:
- Peter Kavsak, PhD, FCACB, FCCS
- Grant/Research Support: Abbott Laboratories, Ortho Clinical Diagnostics, Randox Laboratories, Roche Diagnostics, Siemens Healthcare Diagnostics
- Consultant Fee: Beckman Coulter, Abbott Point of Care, Quidel, Roche, Siemens Healthcare Diagnostics
- Board/Committee Membership/Advisory Board: Roche Diagnostics, Siemens Healthcare Diagnostics
- Presenter/Speaker: Abbott Laboratories, Siemens Healthcare Diagnostics, Thermo Fisher Scientific
- Intellectual Property/Royalty Income: METHOD OF DETERMINING RISK OF AN ADVERSE CARDIAC EVENT (EP 3 341 723 A1)
The following faculty reported no relevant financial relationships:
- Ruben Bonilla Guerrero, MD, DABMG, FACMG, FADLM, MB(ASCP), NY(CQ), CGMBS
- Sara Rogers, PharmD
Content Validity
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
Accreditation Statement
This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID# 4278. This activity was planned in accordance with ACCENT® Standards and Policies.
Successful Completion Statement
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].